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Summary
The multicentre, open-label, two-stage, single-arm, phase 2, PILLAR
(PIvotaL Lymphoma triAls of RAD001)-1 study (NCT00702052) assessed
the efficacy and safety of everolimus 10 mg/d in adults with confirmed
mantle cell lymphoma (MCL) refractory to or intolerant of bortezomib
who received ≥1 other antineoplastic agent, either separately or in combi-
nation with bortezomib. Primary endpoint was overall response rate (ORR)
per investigator review according to the response criteria for malignant
lymphoma. Secondary endpoints included progression-free survival (PFS),
overall survival (OS) and safety. Fifty-eight patients were enrolled from
August 2008–January 2011. Five partial responses were observed (ORR
86%; 90% confidence interval [CI] 35–173%); the study did not meet the
prespecified objective of ≥8 objective responses among 57 patients. Median
PFS and OS were 44 months (95% CI 35–61) and 169 months (95% CI
144–299), respectively. Grade 3/4 non-haematological toxicities occurred
in 707% of patients. Based on laboratory values, grade 3/4 thrombocytope-
nia, neutropenia and anaemia occurred in 138%, 138% and 86% of
patients, respectively. Everolimus demonstrated modest activity and accept-
able tolerability in heavily pretreated patients with MCL refractory to or
intolerant of bortezomib. Future studies evaluating everolimus in a less
refractory population or in combination with other targeted therapies in
refractory MCL are warranted.
Keywords: bortezomib, everolimus, mantle cell lymphoma, mammalian
target of rapamycin, relapsed/refractory disease.
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Mantle cell lymphoma (MCL) is a rare, often aggressive
mature B-cell lymphoma representing 5–10% of all non-
Hodgkin lymphomas (Perez-Galan et al, 2011). Most MCL
are characterized by a t(11;14)(q13;q32) balanced chromo-
somal translocation of the cyclin D1 gene (CCND1) on chro-
mosome 11 to the immunoglobulin heavy chain enhancer
region on chromosome 14, resulting in cyclin D1 overexpres-
sion and increased cell proliferation (Perez-Galan et al,
2011). Aside from this hallmark translocation, MCL fre-
quently involves secondary chromosomal alterations impact-
ing other genes involved in cell cycle regulation and those
implicated in DNA damage response, signal transduction and
apoptosis (Perez-Galan et al, 2011).
MCL typically presents as advanced disease, with common
extranodal manifestations in the gastrointestinal tract, bone
marrow, liver, spleen and Waldeyer ring (Cohen et al, 1998;
Romaguera et al, 2003). Recommended first-line therapy for
advanced MCL is rituximab-based chemotherapy followed by
autologous stem cell transplantation (ASCT) consolidation in
eligible patients (Dreyling et al, 2013; National Comprehen-
sive Cancer Network, Inc, 2013). Despite high response rates,
many patients relapse and often develop chemoresistance.
The response duration of conventional chemotherapy in
relapsed/refractory MCL is typically short, even after high-
dose therapy and ASCT (Perez-Galan et al, 2011). Although
a small subset of patients may experience long-term disease-
free survival after non-myeloablative allogeneic stem cell
transplantation, curative therapy for MCL remains elusive for
the majority of patients (National Comprehensive Cancer
Network, Inc, 2013). The first novel agent approved by the
United States Food and Drug Administration as second-line
therapy for MCL was bortezomib (Fisher et al, 2006; Goy
et al, 2009; O’Connor et al, 2009). In the phase 2 PINNA-
CLE study of MCL patients previously treated with 1 or 2
lines of therapy (N = 155), bortezomib showed a 32% overall
response rate (ORR), 92-month median duration of
response and 67-month median time to progression (Goy
et al, 2009). Based on the results of the phase II EMERGE
study (Goy et al, 2013), lenalidomide was approved in the
United States for the treatment of patients who relapsed
after, or were refractory to, bortezomib. Although other cyto-
toxic regimens are used in this setting, no consensus regard-
ing the optimal strategy exists.
Dysregulation of the mammalian target of rapamycin
(mTOR) pathway is frequently observed in MCL (Rizzatti
et al, 2005; Peponi et al, 2006; Rudelius et al, 2006; Dal et al,
2008), and the cap-dependent translation necessary for cyclin
D1 expression is regulated by this pathway (Bjornsti &
Houghton, 2004; Schatz, 2011). In vitro data have established
that inhibiting mTOR with everolimus induces cell cycle
arrest and reduces 4E-BP1 phosphorylation (Haritunians
et al, 2007). Similar findings have been observed in other
studies of everolimus and the mTOR inhibitors rapamycin
and temsirolimus (Galimberti & Petrini, 2010; Rosich et al,
2012). In one phase 2 study (N = 77), oral everolimus
10 mg/d produced a 30% ORR in patients with relapsed,
aggressive lymphoma, including a 32% ORR in patients with
MCL (n = 19) (Witzig et al, 2011). Everolimus was generally
well tolerated, and most toxicities were manageable with
temporary dose adjustment. A second phase 2 study also
found everolimus to be well tolerated with clinical activity
against relapsed/refractory MCL (Renner et al, 2012). In a
randomized, open-label, phase 3 study (N = 162), intrave-
nous temsirolimus 175 mg/week for 3 weeks followed by
75 mg/week thereafter (175/75-mg regimen) significantly
prolonged progression-free survival (PFS) compared with the
investigator’s choice of 1 of 11 prospectively defined single-
agent treatment options (48 months vs. 19 months;
P = 0009) and increased ORR (22% vs. 2%; P = 00019)
(Hess et al, 2009). Although thrombocytopenia, asthenia and
diarrhoea occurred more often with temsirolimus than the
investigator’s choice (P ≤ 0041), the overall safety profile
was considered manageable. Based on these results, temsiroli-
mus was approved by the European Medicines Agency for
the treatment of relapsed/refractory MCL (http://www.ema.
europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000799/WC500039912.pdf).
This phase 2 study was designed to evaluate everolimus
efficacy and safety in patients with MCL who were intolerant
of or refractory to bortezomib.
Methods
Study design and patients
PILLAR (PIvotaL Lymphoma triAls of RAD001)-1 was a
multicentre, open-label, two-stage, single-arm, phase 2 study
conducted in the United States (ClinicalTrials.gov identifier
NCT00702052). Inclusion criteria included age ≥18 years;
histopathologically confirmed (central pathology review) MCL
with staining for cyclin D1 overexpression or cytogenetic evi-
dence of the t(11;14)(q13;q32) translocation, documented
bortezomib-refractory disease or bortezomib intolerance and
receipt of ≥1 other antineoplastic agent given either separately
or with bortezomib. Patients were considered bortezomib
refractory if they had documented radiological progression on
or within 12 months of the last bortezomib dose when given
alone or as the last component of combination therapy includ-
ing bortezomib. Patients were considered bortezomib intoler-
ant if they discontinued bortezomib due to documented
toxicity. Other inclusion criteria included ≥1 nodal site of
measurable disease >20 cm; Eastern Cooperative Oncology
Group (ECOG) performance status 0–2; life expectancy
≥3 months; and adequate bone marrow, hepatic and renal
function. Exclusion criteria included unresolved grade 3/4
toxicity from antineoplastic therapies, anticancer therapy or
other investigational agent taken within 4 weeks of study
start, previous mTOR inhibitor treatment, previous alloge-
neic stem cell transplant, presence or history of central ner-
vous system lymphoma, chronic immunosuppressive therapy
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excluding topical or inhaled corticosteroids and any active
bleeding diathesis or other serious and/or uncontrolled medi-
cal condition.
This study was conducted in accordance with the Interna-
tional Conference on Harmonization Harmonized Tripartite
Guidelines for Good Clinical Practice, applicable local regula-
tions and the Declaration of Helsinki. The protocol and all
amendments were reviewed and approved by the institutional
review board of each centre. All patients provided written
informed consent before enrolment.
Procedures
Patients received oral everolimus 10 mg once daily until dis-
ease progression per investigator review, unacceptable toxic-
ity, death or discontinuation for other reason. Dose
reductions and/or interruptions according to an algorithm
outlined in the study protocol were permitted for intolerable
toxicity.
Computed tomography scan of the chest, abdomen and
pelvis with radiological tumour evaluation was performed at
screening, every 8 weeks (1 week) for the first year of
study treatment and every 12 weeks (1 week) thereafter
until initiation of new anticancer therapy. Response was also
assessed at end of treatment. Adverse events (AEs) were
monitored continuously throughout the study and for 28 d
after the last study drug dose. Serum chemistry, coagulation,
complete blood count (CBC) and serum lipid profiles were
assessed at baseline, every 4 weeks during treatment and at
the end of treatment. Routine CBCs were also assessed every
2 weeks for the first 12 weeks. All patients were followed
monthly for survival until the date of final analysis (20
April, 2012).
Venous blood samples (2 ml) for pharmacokinetic analysis
were collected in EDTA-containing tubes pre-dose on day 15
and at times of tumour assessment to assess everolimus
trough concentrations (Cmin). Samples were also collected at
1 and 2 h post-dose on day 15 to capture the near-maximum
everolimus concentration (Cmax). If samples were not
obtained at the specified visit, they were collected at the next
scheduled visit. On days of sample collection, everolimus
administration was supervised by study centre personnel. All
blood samples were stored at 20C within 1 h of collection.
Everolimus concentrations in whole blood were determined
at a central laboratory (WuXi Apptec, Shanghai, China)
using a liquid chromatography-mass spectrometry method
following liquid extraction (lower limit of quantification,
03 ng/ml).
Statistical analysis
Efficacy was assessed in the full analysis set (i.e. all patients
who received ≥1 dose of study drug). Safety was assessed in
the safety set (i.e. all patients who received ≥1 dose of study
drug and had ≥1 valid postbaseline safety assessment).
The primary study endpoint was ORR, assessed by the
investigator and defined as the percentage of patients with a
complete response (CR) or partial response (PR) according
to response criteria for malignant lymphoma based on Che-
son (Cheson et al, 1999; Cheson, 2007). Sensitivity analyses
were based on central radiology review. Secondary endpoints
included duration of response (DOR), PFS, OS and safety
and tolerability. DOR was defined as the time from first doc-
umented response (CR or PR) to the time of first docu-
mented progression or death due to lymphoma; patients
without disease progression or who died from causes other
than lymphoma were censored (indicated by “+”) at the time
of last valid tumour assessment. PFS was defined as the time
from start of study treatment to the time of first documented
disease progression or death due to any cause; patients were
censored at the time of last valid tumour assessment in the
absence of progression or death. OS was defined as the time
from start of study treatment to the time of death due to
any cause; patients lost to follow-up or alive at the analysis
cut-off date were censored at their last contact date. AEs and
laboratory abnormalities were assessed according to the
Common Terminology Criteria for Adverse Events, version
30 (http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/docs/ctcaev3.pdf).
The Kaplan-Meier method was used to analyse time-
to-event endpoints and to estimate median values and
corresponding 95% confidence intervals (CIs). A Cox pro-
portional model was used to analyse the relationship between
average Cmin and time to disease progression and select AEs.
Average Cmin was calculated as a time average over the trial
period until the event, accounting for dose adjustments.
Simon’s 2-stage minimax design was adopted to permit
early termination for futility. The targeted ORR in the full
analysis set was 20%; an ORR ≤7% would preclude further
investigation. Assuming a 5% significance level and 90%
power, 34 patients were to receive study treatment in the first
stage. If ≤2 patients achieved response, the study was to be
terminated. Otherwise, 23 additional patients were to be
enrolled and receive treatment. If ≥8/57 enrolled patients
experienced a response, everolimus would be considered of
clinical interest in this population.
Role of the funding source
The sponsor helped to design the study and to collect, ana-
lyse and interpret the data and provided funding for medical
writing assistance in the preparation of this report. As
authors, employees of the sponsor contributed to the deci-
sion to submit the manuscript. All authors had access to the
data and approved the manuscript for submission.
Results
Between 22 August, 2008, and 18 January, 2011, 58 patients
were enrolled from 26 centres in the United States and
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received ≥1 everolimus dose. Table I shows the baseline
demographics and disease characteristics of the patients.
Forty-nine patients (845%) were bortezomib refractory and
eight patients (138%) were intolerant of bortezomib; one
patient could not be classified as either because disease pro-
gression occurred >12 months after the last bortezomib dose.
At initial diagnosis, 190% and 672% of patients presented
with stage III and IV disease, respectively. Before enrolment,
all patients received >1 antineoplastic therapy, including
741% who received ≥3 and 207% who received ASCT. All
patients were included in both the full analysis and safety
sets. Median follow-up duration (time from median treat-
ment start date to final analysis date [20 April, 2012]) was
232 months. At final analysis, all patients discontinued treat-
ment, most commonly because of disease progression or AEs
(Table II). After study drug discontinuation, 42 patients
(724%) received further antineoplastic therapy.
As of 26 April, 2010, stage 1 was declared successful, with
3/26 enrolled patients achieving PR per investigator review
(before the 34-patient target); this permitted uninterrupted
recruitment in stage 2. At final analysis and per investigator
review, best overall response was PR in 5 patients (ORR
86%; 90% CI 35–173%) (Table III). DOR ranged from
07–111+ months. Four patients proceeded to stem cell
transplantation following study completion (allogeneic trans-
plantation, n = 3; unknown type, n = 1). Median PFS per
investigator review was 44 months (95% CI 35–61 months)
(Fig. 1A). Median OS was 169 months (95% CI 144–299)
(Fig. 1B).
In a sensitivity analysis based on central radiology review,
six patients achieved PR (ORR 103%; 90% CI 46–194%)
(Table III). Per central review, DOR ranged from 16+
months to 132+ months and median PFS was 52 months
(95% CI 40–71 months).
Median everolimus treatment duration and dose intensity
were 870 d and 92 mg/d, respectively. Dose interruptions
and/or reductions were required by 34 patients (586%), most
commonly as the result of AEs (552%). All patients experi-
enced ≥1 AE, including 810% who experienced ≥1 grade 3/4
AE (Table IV). Grade 3/4 non-haematological AEs occurred
in 707% of patients and included pneumonia (86%),
abdominal pain (86%) and fatigue (69%). Pneumonitis of
all grades occurred in 7 patients (121%), with a greatest
severity of grade 3 (n = 3; 52%); 3 of these 7 patients discon-
tinued everolimus. Based on laboratory values, 57 patients
(983%) experienced a haematological AE, including 23
(397%) who experienced a grade 3/4 event (Table V). The
most frequently reported haematological laboratory abnor-
mality was anaemia (845% any grade, 86% grade 3/4), fol-
lowed by thrombocytopenia (759% any grade, 138% grade
3/4). Seven deaths (all due to lymphoma) occurred within
28 days of the last everolimus dose.
Everolimus Cmin values, assessed by actual dose at time of
assessment, were mostly stable over time, although fluctuation
Table I. Baseline patient demographics and disease history in the full
analysis set.
Everolimus
N = 58
Age in years, median (range) 680 (500–830)
Age, years
<65 23 (397)
≥65 35 (603)
Gender
Male 45 (776)
Female 13 (224)
Race
White 52 (897)
Black 3 (52)
Asian 1 (17)
Other 2 (34)
Eastern Cooperative Oncology Group performance status
0 25 (431)
1 31 (534)
≥2 2 (35)
Bulk >10 cm at initial diagnosis 10 (172)
Bortezomib refractory or intolerant
Refractory 49 (845)
Intolerant 8 (138)
Neither 1 (17)
Lactate dehydrogenase ≥ upper limit of normal 7 (121)
Time since initial diagnosis
Median (range), months 555 (82–1363)
>6 months to ≤2 years 8 (138)
>2 years to ≤5 years 24 (414)
>5 years 26 (448)
Time since most recent recurrence/relapse
≤6 months 53 (914)
>6 months to ≤12 months 3 (52)
>12 months 2 (34)
Stage at initial diagnosis
IA/IB 1 (17)/1 (17)
IIA 2 (34)
IIIA/B 9 (155)/2 (34)
IVA/B 30 (517)/9 (155)
Missing 4 (69)
MIPI risk
Low (score <57) 28 (483)
Intermediate (score ≥57 to <62) 23 (397)
High (score ≥62) 7 (121)
Number of organs involved other than lymph nodes
0 32 (552)
1 22 (379)
2 4 (69)
Prior lymphoma bone marrow tumour
involvement
39 (672)
Number of previous treatment regimens
1 0
2 15 (259)
3 20 (345)
>3 23 (397)
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during the first 12 weeks was observed among patients receiv-
ing everolimus 10 mg/d (Fig. 2). An approximately dose-
proportional increase in steady state Cmax from everolimus
5 mg/d to 10 mg/d was noted (median [range] 237
[171–302] ng/ml and 490 [172–1030] ng/ml, respectively).
Cox proportional hazards analysis showed no significant
relationship between time-normalized Cmin and risk of disease
progression (risk ratio for twofold Cmin increase 0708; 95%
CI 0297–1685) or risk of experiencing selected clinically
notable AEs (i.e. elevated creatinine, infections and infesta-
tions, neutropenia, non-infectious pneumonitis, renal events,
stomatitis and thrombocytopenia [data not shown]). Caution
should be used when the exposure-safety results are inter-
preted because of the low incidence of certain AEs.
Discussion
In the phase 2 PILLAR-1 study of 58 patients with heavily pre-
treated MCL refractory to or intolerant of bortezomib,
5 patients experienced PR with everolimus, which was below the
targeted ≥8 responses out of 57 patients required to declare
everolimus worthy of further study in this population. The
ORR was 86% (90% CI 35–173%), which was lower than the
32% (Witzig et al, 2011) and 20% (Renner et al, 2012) ORRs
reported in other phase 2 studies of everolimus for previously
treated MCL, the 41% (Ansell et al, 2008) and 38% (Witzig
et al, 2005) ORRs reported in the phase 2 studies of temsiroli-
mus and the 22% ORR reported in the phase 3 temsirolimus
study (Hess et al, 2009). It is interesting to note that, although
median PFS in PILLAR-1 was less than that reported in the
phase 2 study of temsirolimus published by Witzig et al (2005)
(44 months and 65 months, respectively), it was similar to
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Fig 1. Progression-free survival based on local radiology review (A)
and overall survival (B) in the full analysis set.
Table I. (Continued)
Everolimus
N = 58
Prior antineoplastic therapy 58 (100)
Chemotherapy 58 (100)
1 regimen 19 (328)
2 regimens 16 (276)
≥3 regimens 23 (397)
Surgery 12 (207)
Rituximab 57 (983)
Radiotherapy 14 (241)
Autologous stem cell transplant 12 (207)
MIPI, Mantle Cell Lymphoma International Prognostic Index.
Data are given as number (%) unless otherwise stated.
Table II. Patient disposition as of 20 April, 2012.
Everolimus
N = 58
Discontinued study treatment 58 (100)
Disease progression 30 (517)
Adverse events(s) 23 (397)
Subject withdrew consent 5 (86)
Entered post-treatment evaluation 40 (690)
Discontinued from post-treatment evaluation 40 (100*)
New anticancer therapy 32 (800*)
Death 5 (125*)
Administrative reasons 3 (75*)
Data are given as number (%).
*Denominator is the number of patients who discontinued the post-
treatment evaluation period.
Table III. Best overall response per investigator and central review
in the full analysis set.
Best overall response
Everolimus
N = 58
Investigator
review
Central
review
Overall response rate, % (90% CI*) 86 (35–173) 103 (46–194)
Complete response 0 0
Partial response 5 (86) 6 (103)
Stable disease 35 (603) 30 (517)
Progressive disease 8 (138) 9 (155)
Unknown 10 (172) 13 (224)
Data are given as number (%) unless otherwise stated.
*Exact (Clopper Pearson) 90% confidence interval (CI).
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that reported by Hess et al (2009) for the 175/75-mg temsiroli-
mus regimen in the phase 3 trial (48 months). The PFS
observed in PILLAR-1 was also similar to the 40-month
median PFS recently reported in the phase 2 EMERGE study of
lenalidomide for patients who relapsed after or were refractory
to bortezomib (Goy et al, 2013). Additionally, the median OS
in PILLAR-1 was longer than that reported in any of the temsi-
rolimus trials (169 months vs. 12 months (Witzig et al,
2005), 14 months (Ansell et al, 2008) and 128 months with
temsirolimus 175/75 mg (Hess et al, 2009)). Although it is not
clear why the PILLAR-1 ORR was lower than in other studies
of mTOR inhibitors in this setting, it is possible that the
enrolment of a high percentage of patients with bortezomib-
refractory disease (845%) resulted in a more heavily pre-
treated, higher-risk population than that enrolled in previous
studies of mTOR inhibitors for relapsed/refractory MCL. Only
23% of patients in the phase 3 temsirolimus study had prior
bortezomib therapy (Hess et al, 2009). Although not reported,
the percentage of patients previously treated with bortezomib
in the phase 2 temsirolimus trials was probably very low
because these studies were conducted before bortezomib was
approved for treating MCL (Witzig et al, 2005; Ansell et al,
2008). In PILLAR-1, 741% of patients received ≥3 previous
treatment regimens, similar to the 783% of patients enrolled
in the EMERGE study who received ≥3 previous treatment
regimens (Goy et al, 2013). In the trials of temsirolimus, the
median number of therapies ranged from 3 (Witzig et al, 2005;
Hess et al, 2009) to 4 (Ansell et al, 2008). Compared with the
phase 2 temsirolimus trial published by Witzig et al (2005),
almost twice as many patients in PILLAR-1 had undergone
previous ASCT (11% vs. 207%).
It is also clear that MCL is a very heterogeneous disease.
Previous studies (Rosenwald et al, 2003; Katzenberger et al,
2008) have shown that the proliferation index can be used to
sub-classify MCL into different clinical and prognostic enti-
ties. Patients with more proliferative disease, as determined
Table IV. Non-haematological adverse events occurring in >10% of
patients regardless of relationship to study drug in the safety set.
Everolimus
N = 58
All grades Grade 3 Grade 4
Any adverse event 58 (100) 35 (603) 12 (207)
Diarrhoea 26 (448) 3 (52) 0
Fatigue 25 (431) 4 (69) 0
Nausea 16 (276) 0 0
Peripheral oedema 16 (276) 1 (17) 0
Rash 16 (276) 2 (34) 0
Dyspnoea 14 (241) 3 (52) 0
Decreased appetite 13 (224) 1 (17) 0
Abdominal pain 12 (207) 4 (69) 1 (17)
Cough 12 (207) 0 0
Pyrexia 12 (207) 1 (17) 0
Stomatitis 12 (207) 1 (17) 0
Headache 11 (190) 2 (34) 0
Pneumonia 10 (172) 5 (86) 0
Vomiting 10 (172) 1 (17) 0
Arthralgia 9 (155) 0 0
Asthenia 9 (155) 3 (52) 0
Constipation 9 (155) 0 0
Dizziness 9 (155) 0 0
Dysgeusia 8 (138) 0 0
Hyperglycaemia 8 (138) 3 (52) 1 (17)
Weight decreased 8 (138) 1 (17) 0
Dry mouth 7 (121) 0 0
Epistaxis 7 (121) 0 0
Pneumonitis 7 (121) 3 (52) 0
Upper respiratory tract infection 7 (121) 0 0
Back pain 6 (103) 1 (17) 0
Dehydration 6 (103) 2 (34) 0
Hypercholesterolaemia 6 (103) 1 (17) 1 (17)
Insomnia 6 (103) 0 0
Oropharyngeal pain 6 (103) 0 0
Pain in extremity 6 (103) 0 0
Blurred vision 6 (103) 0 0
Data are given as number (%).
Table V. Haematological laboratory abnormalities regardless of rela-
tionship to study drug in the safety set.
Everolimus
N = 58
All grades Grade 3 Grade 4
Any 57 (983) 12 (207) 11 (190)
Anaemia 49 (845) 4 (69) 1 (17)
Thrombocytopenia 44 (759) 4 (69) 4 (69)
White blood cells decreased 37 (638) 7 (121) 1 (17)
Lymphopenia 32 (552) 9 (155) 4 (69)
Neutropenia 28 (483) 4 (69) 4 (69)
Data are given as number (%).
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Fig 2. Longitudinal everolimus Cmin values by actual dose at the time
of sampling in the safety set. Aside from Cycle (C) 5, Day (D) 1, no
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assessment; therefore, only 1 data point is available for this dosage.
Everolimus for bortezomib-refractory mantle cell lymphoma
ª 2014 John Wiley & Sons Ltd 515
British Journal of Haematology, 2014, 165, 510–518
by gene expression profiling or Ki-67 staining, are known to
have a worse prognosis and more aggressive disease. Patients
with a lower proliferative index are known to have a substan-
tially better prognosis and may be managed in a manner
similar to those with other indolent lymphomas (Martin &
Leonard, 2011). Given this biological diversity, it is conceiv-
able that variability in the proportion of patients with highly
versus less proliferative disease could influence the outcome
of a drug known to have a marked impact on this underlying
biology.
Another possible explanation related to MCL heterogene-
ity is that fewer patients in PILLAR-1 may have had disease
with constitutive mTOR pathway activation, rendering them
less responsive to mTOR inhibition with everolimus.
Although predictive biomarkers for efficacy of mTOR inhib-
itors in lymphoma have not been clearly established, pre-
clinical data suggest that tumour cells with constitutive
mTOR pathway activation are more responsive to mTOR
inhibitors (Di Nicolantonio et al, 2010; Weigelt et al, 2011;
Meric-Bernstam et al, 2012). Supportive clinical data come
from whole genome and capture-based sequencing per-
formed on DNA samples collected from 14 patients enrolled
in a phase 2 study of everolimus for metastatic bladder
cancer (Iyer et al, 2012). In that study, patients whose
tumours harboured mutations in TSC1, a gene encoding
one half of the hamartin/tuberin tumour suppressor com-
plex that lies upstream of mTOR, had a longer duration of
everolimus therapy than those with TSC1 wild-type tumours
(77 vs. 20 months; P = 0004) and a significantly longer
time to recurrence (41 vs. 18 months; P = 0001).
Everolimus demonstrated acceptable tolerability in this
heavily pretreated, bortezomib-refractory/intolerant popula-
tion, with no new safety findings. The toxicities observed
were similar to those previously reported in patients receiv-
ing mTOR inhibitors, were reversible and were effectively
managed with either dose adjustment or use of supportive
therapies. The incidence of grade 3/4 non-haematological
AEs in this study (707%) was somewhat higher than that
reported by Witzig et al (2011) (53%), although the inci-
dence of the most commonly observed grade 3/4 AEs was
similar (Witzig et al, 2011). Conversely, the incidence of
grade 3/4 haematological AEs in this study (397% as
assessed by laboratory abnormalities) was somewhat less than
the 56% incidence reported by Witzig et al (2011). Addition-
ally, rates of grade 3/4 thrombocytopenia, neutropenia and
anaemia in PILLAR-1 (138%, 138% and 86%, respectively)
compare favourably with those reported previously (38%,
18% and 14%, respectively) (Witzig et al, 2011). Individual
grade 3/4 haematological AEs were also more common in
the trials of temsirolimus for MCL, with 39–66% of patients
experiencing thrombocytopenia, 14–26% experiencing anae-
mia and 15–29% experiencing neutropenia (Witzig et al,
2005; Ansell et al, 2008; Hess et al, 2009).
Although PILLAR-1 demonstrated moderate clinical activ-
ity for everolimus monotherapy in bortezomib-refractory or
intolerant MCL, the activity observed in this study and previ-
ously noted with other mTOR inhibitors (Witzig et al, 2005,
2011; Ansell et al, 2008; Hess et al, 2009; Renner et al, 2012)
suggests a possible role for mTOR inhibition in MCL. It is
possible that everolimus may demonstrate improved efficacy
in a less refractory population or in patients whose disease
demonstrates constitutive mTOR pathway activity. Given the
profound prognostic impact of the proliferation index in
MCL and the likelihood that different MCL subsets will
respond differently to drugs targeting pathways involved in
cellular proliferation, future MCL studies should include
some measurement of the proliferation index. Combination
therapy with everolimus should also be considered. In
human MCL cell lines, synergistic cytotoxic activity was
observed when everolimus was combined with various agents
already used to treat MCL, including doxorubicin, vincris-
tine, paclitaxel, rituximab, bortezomib and vorinostat (Harit-
unians et al, 2007). Preclinical data from human MCL cell
lines also suggest that simultaneously inhibiting PI3K and
mTOR could lead to more effective MCL treatment
(Civallero et al, 2012; Kim et al, 2012). Data from clinical trials
of temsirolimus-based combination therapy appear to confirm
the merit of assessing everolimus-based combinations. In a
phase 2 study of patients with relapsed or refractory MCL,
temsirolimus plus rituximab was associated with acceptable
tolerability, provided an ORR of 594% and median time to
progression of 97 months and was associated with a median
OS of 295 months (Ansell et al, 2011). Preliminary data
from a phase I/II study also suggest a possible benefit for the
combination of temsirolimus, bendamustine and rituximab
(Hess et al, 2011). Ongoing trials are assessing temsirolimus
in combination with R-CHOP (rituximab, cyclophospha-
mide, doxorubicin, vincristine, prednisolone), R-FC
(rituximab, fludarabine, cyclophosphamide) or R-DHA
(rituximab, high-dose cytarabine, dexamethasone
(NCT01389427); bortezomib, rituximab and dexamethasone
(NCT01381692); and lenalidomide (NCT01076543);
everolimus is being assessed in combination with panobino-
stat (NCT00918333 and NCT00967044), idelalisib
(NCT01088048) and lenalidomide (NCT01075321).
In conclusion, everolimus monotherapy demonstrated
modest activity and acceptable tolerability in patients with
heavily pretreated, bortezomib-refractory or -intolerant MCL.
Future studies exploring everolimus as monotherapy in a less
refractory population or in combination with chemotherapy
or other targeted therapies for refractory MCL are warranted.
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